Eman M. Mansory , Lotus Alphonsus , Janine R. Hutson , Barbra de Vrijer , Alejandro Lazo-Langner
{"title":"Anticoagulant prophylaxis in pregnant women with a history of venous thromboembolism: A systematic review and meta-analysis","authors":"Eman M. Mansory , Lotus Alphonsus , Janine R. Hutson , Barbra de Vrijer , Alejandro Lazo-Langner","doi":"10.1016/j.tru.2023.100150","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Venous thromboembolism (VTE) remains one of the leading causes of morbidity and mortality during pregnancy and the postpartum period. Despite that, the prevention and management of VTEs in pregnant patients is an area of great debate.</p></div><div><h3>Objectives</h3><p>The aim of this systematic review was to evaluate the risk of VTE recurrence during pregnancy for pregnant patients with prior personal history of VTE and the effect of LMWH on such risk.</p></div><div><h3>Methods</h3><p>MEDLINE and EMBASE were searched between January 2000 to December 2022. We included studies that evaluated pregnant patients with previous personal history of VTE and assessed VTE recurrence with or without thromboprophylaxis. A meta-analysis of proportions was done through a Freeman–Tukey transformation using random effect models.</p></div><div><h3>Results</h3><p>30 studies were included in this systematic review. The studies included 5075 pregnant patients with a previous history of DVT or PE. We found a wide variability in thromboprophylaxis strategies<strong>.</strong> The estimated pooled proportions of VTE recurrence were 2.5% (95% CI 1.8–3.3) in patients who were consistently on anticoagulation during pregnancy (pre- and post-partum), 4.7% (95% CI 1.8–8.8) in patients who received anticoagulation in the postpartum period only, and 13.6% (95% CI 6.5 to 22.8) in patients who were not on anticoagulation.</p></div><div><h3>Conclusions</h3><p>In patients with a previous VTE history receiving prophylactic anticoagulation (either both pre- and post-partum or post-partum only), the estimates of VTE recurrence were lower than for patients who did not receive prophylaxis, however, a direct comparison was not possible. The optimal thromboprophylaxis strategy remains unknown.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572723000214/pdfft?md5=24e29ffb56353417a644f81865af1fdb&pid=1-s2.0-S2666572723000214-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572723000214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Venous thromboembolism (VTE) remains one of the leading causes of morbidity and mortality during pregnancy and the postpartum period. Despite that, the prevention and management of VTEs in pregnant patients is an area of great debate.
Objectives
The aim of this systematic review was to evaluate the risk of VTE recurrence during pregnancy for pregnant patients with prior personal history of VTE and the effect of LMWH on such risk.
Methods
MEDLINE and EMBASE were searched between January 2000 to December 2022. We included studies that evaluated pregnant patients with previous personal history of VTE and assessed VTE recurrence with or without thromboprophylaxis. A meta-analysis of proportions was done through a Freeman–Tukey transformation using random effect models.
Results
30 studies were included in this systematic review. The studies included 5075 pregnant patients with a previous history of DVT or PE. We found a wide variability in thromboprophylaxis strategies. The estimated pooled proportions of VTE recurrence were 2.5% (95% CI 1.8–3.3) in patients who were consistently on anticoagulation during pregnancy (pre- and post-partum), 4.7% (95% CI 1.8–8.8) in patients who received anticoagulation in the postpartum period only, and 13.6% (95% CI 6.5 to 22.8) in patients who were not on anticoagulation.
Conclusions
In patients with a previous VTE history receiving prophylactic anticoagulation (either both pre- and post-partum or post-partum only), the estimates of VTE recurrence were lower than for patients who did not receive prophylaxis, however, a direct comparison was not possible. The optimal thromboprophylaxis strategy remains unknown.
背景:静脉血栓栓塞(VTE)仍然是妊娠和产后发病和死亡的主要原因之一。尽管如此,孕妇静脉血栓栓塞的预防和管理仍是一个有很大争议的领域。目的本系统综述的目的是评估有静脉血栓栓塞个人病史的孕妇在妊娠期间静脉血栓栓塞复发的风险以及低分子肝素对这种风险的影响。方法检索2000年1月至2022年12月的medline和EMBASE数据库。我们纳入的研究评估了有静脉血栓栓塞病史的孕妇,并评估了静脉血栓栓塞复发是否有血栓预防。采用随机效应模型,通过Freeman-Tukey变换对比例进行了荟萃分析。结果本系统综述纳入了30项研究。这些研究包括5075名有深静脉血栓或肺动脉栓塞病史的孕妇。我们发现血栓预防策略存在很大差异。在妊娠期间(产前和产后)持续使用抗凝治疗的患者中,静脉血栓栓塞复发的估计总比例为2.5% (95% CI 1.8-3.3),仅在产后接受抗凝治疗的患者中为4.7% (95% CI 1.8-8.8),未使用抗凝治疗的患者中为13.6% (95% CI 6.5 - 22.8)。结论有静脉血栓栓塞史的患者接受预防性抗凝治疗(产前和产后或仅产后),静脉血栓栓塞复发的估计低于未接受预防性抗凝治疗的患者,但无法进行直接比较。最佳的血栓预防策略仍然未知。